Bibliography
- AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
- MCLeske, AHeijl, MHussein, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48-56
- MAKass, DKHeuer, EJHigginbotham, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
- SMiglior, TZeyen, NPfeiffer, et al. Results of the European glaucoma prevention study. Ophthalmology 2005;112:366-75
- European Glaucoma Society. Terminology and Guidelines for Glaucoma. In: European Glaucoma Society Guidelines. 4th edition. Editrice DOGMA; Savona, Italy: 2014. p. 117-53
- CBaudouin, ALabbé, HLiang, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29:312-34
- PJPisella, PPouliquen, CBaudouin. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418-23
- CBaudouin. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86:716-26
- GCRossi, GMPasinetti, LScudeller, et al. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol 2013;23:296-302
- ALabbe, APauly, HLiang, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 2006;22:267-78
- FBrignole-Baudouin, HLiang, LRiancho, CBaudouin. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK preserved ophthalmic solutions on human conjunctival epithelial cells. Curr Eye Res 2011;36:979-88
- HLiang, FBrignole-Baudouin, LRiancho, CBaudouin. Reduced in vivo ocular surface toxicity with polyquad preserved travoprost versus benzalkonium preserved travoprost or latanoprost ophthalmic solutions. Ophthalmic Res 2012;48:89-101
- SGandolfi, TParedes, IGoldberg, et al. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol 2012;22:34-44
- GRossi, GMPasinetti, LScudeller, PEBianchi. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther 2013;29:390-4
- RMShiffman, MDChristianson, GJacobsen, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol 2000;118:615-21
- MYKahook, RNoecker. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther 2008;25:743-51
- International Dry Eye Workshop (DEWS). The epidemiology of dry eye disease. Ocul Surf 2007;5:93-107
- AGIS investigators. the Advanced Glaucoma Intervention Study (AGIS):14. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophtalmol 2002;134:499-512